Corcept Therapeutics. has been granted a patent for a class of pyrimidinedione cyclohexenyl compounds, which are identified as glucocorticoid receptor modulators. The patent includes specific claims regarding the chemical structure of these compounds. GlobalData’s report on Corcept Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Corcept Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Corcept Therapeutics's grant share as of July 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Pyrimidinedione compounds as glucocorticoid receptor modulators
The granted patent US12018001B2 outlines a novel compound characterized by a specific chemical formula, referred to as formula Ic-1. The claims detail various structural components of the compound, particularly focusing on the substituents represented as Rb, which can independently be a range of groups including hydrogen, halogens, cyano groups, and various alkyl and alkoxy chains. The claims further elaborate on the potential variations of Rb, allowing for a diverse array of chemical modifications that could enhance the compound's properties. Additionally, the claims specify that R1 can be hydrogen, indicating further structural flexibility.
Moreover, the patent includes claims for pharmaceutical compositions that incorporate the compound of formula Ic-1 alongside one or more pharmaceutically acceptable excipients. This suggests potential applications in therapeutic contexts, although specific uses are not detailed in the claims. The patent emphasizes the versatility of the compound through its various forms and substituents, which may contribute to its efficacy in pharmaceutical applications. Overall, the claims present a comprehensive framework for the compound's structure and potential utility in medicinal chemistry.
To know more about GlobalData’s detailed insights on Corcept Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
